Lung Cancer News
-
Puma Biotechnology Inc., the maker of an experimental cancer drug, had its biggest two-day gain in seven months after data on a competitor medicine did nothing to diminish analysts’ expectations.
-
Merck KGaA hasn’t ruled out pursuing its therapeutic cancer vaccine L-BLP25 after a trial showed the treatment prolonged the lives of a group of advanced lung cancer patients by 50 percent compared with placebo.
-
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
-
Should patients undergoing broad DNA testing for a specific ailment be told of unexpected findings that signal risk of cancer or other serious diseases, even if they don’t request the information?
-
AstraZeneca Plc will move three experimental cancer treatments into late-stage development as generic competition for its best-selling drugs intensifies.
-
Middle-aged men who stayed fit were less likely to die from three common cancers after being diagnosed than those who were out of shape, research found.
-
Roche Holding AG, the world’s biggest maker of cancer drugs, won U.S. approval to sell a gene mutation test that can help doctors pinpoint patients’ likelihood to respond to a popular treatment for lung cancer.
-
Swiss stocks rose for a second day, extending the benchmark Swiss Market Index’s highest level in more than five years.
-
Merck & Co., Bristol-Myers Squibb Co. and Roche Holding AG have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.
-
A novel test from Genomic Health Inc. helps predict whether prostate cancer is aggressive or slow- growing, giving patients and doctors more information to shape treatment for the most common tumor found in men, a study found.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page